KRAS and gastric cancer: Furthermore, frequency of MYC gain in tumors of patients with advanced GC seems to be higher in the Brazilian population [48–53] than in Asia, where Deng et al. [54] demonstrated the existence of five distinct gastric cancer patient subgroups, defined by the signature genomic alterations (FGFR2 [9% of tumours], KRAS [9%], EGFR [8%], ERBB2 [7%] and MET [4%]); however MYC was not one of them.